Firmenich Opens New Biotechnology and Naturals Pilot Plant and Laboratory in Geneva

Firmenich | October 01, 2020

Firmenich, the world's largest privately-owned Perfume and Taste company, is proud to announce the opening of its new biotechnology and naturals pilot plant and laboratory in Geneva. Benefiting from the latest digital technology, the facility opens a new era for the development of ingredients and clean label solutions by providing faster speed-to-market and greater flexibility for customer collaboration. Integrated into the Group's flagship ingredients production site at La Plaine, Geneva, the facility operates to the highest safety and environmental standards, reducing waste and energy consumption. "With our new biotechnology pilot plant closely connected with the ingredients production site, Firmenich provides integrated biotech development all the way down to the finished product, without any gaps," said Genevieve Berger, Chief Research Officer, Firmenich. "Opening a new era in ingredients creation, our pilot plant and laboratory harnesses new technologies to improve clean label solutions, while the latest digital innovation maximizes efficiency." "Our new pilot plant provides greater flexibility to respond to customer needs in product development," said Sarah Reisinger, Senior Vice President Research Operations, Firmenich. "Capable of handling multiple projects simultaneously, it also enables small scale production of trial batches for formulation or testing and regulatory validation." Operational this month, the pilot plant at La Plaine is a cornerstone for new ingredients for both perfumery and flavors, enabling the development of the most efficient and high-quality production processes through biotechnology or natural extraction. Harnessing digital technology for increased automation, the pilot plant is able to move from single to continuous batch process, increasing efficiency, speed and reducing the use of raw materials.

Spotlight

Biotechnology, described as “the manipulation of microorganisms to perform certain processes,” is developing very quickly, but public opinion and acceptance of it may not be evolving as fast. In fact the more we hear about biotechnology, the more it seems we hear an outcry against it. However, this opposition may be less pervasive than we think, or may only need a better education around the topic. While public opinion informs many things from policy to law, it is very important we make sure these opinions are formed by informed citizens, and not based in emotions such as fear.

Spotlight

Biotechnology, described as “the manipulation of microorganisms to perform certain processes,” is developing very quickly, but public opinion and acceptance of it may not be evolving as fast. In fact the more we hear about biotechnology, the more it seems we hear an outcry against it. However, this opposition may be less pervasive than we think, or may only need a better education around the topic. While public opinion informs many things from policy to law, it is very important we make sure these opinions are formed by informed citizens, and not based in emotions such as fear.

Related News

INDUSTRIAL IMPACT

n-Lorem Foundation Partners with Argonaut to Manufacture ASO Medicines for Patients with Nano-rare Diseases

Argonaut Manufacturing Services | February 02, 2022

Argonaut Manufacturing Services, a leading contract manufacturing organization, and n-Lorem, a nonprofit foundation, today announced a new partnership that supports and reduces the cost of manufacturing of n-Lorem’s experimental antisense oligonucleotide medicines developed for nano-rare disease patients for free, for life. “Providing nano-rare patients, who would otherwise be largely ignored by our current drug discovery paradigm, with a personalized approach for free is a remarkable undertaking and one that requires the commitment of many people and organizations. We are pleased to add Argonaut to our growing list of the industry’s best to support the highest-quality drug discovery, development, and manufacturing for our patients. Reducing the cost of manufacturing translates into lower per-patient costs, which is important for our non-profit and important for our patients who depend upon us and our partners. At n-Lorem, we are fortunate that our partners can integrate seamlessly and efficiently with us and together we work toward making a difference for our nano-rare patient today and tomorrow.” Stanley T. Crooke, M.D., Ph.D., Founder, CEO and Chairman of n-Lorem Foundation “At Argonaut, we are incredibly proud to be working with this distinguished group of experts at the n-Lorem Foundation. We are focused on delivering the best contract manufacturing support to the innovators and creators, in the biopharma industry. Partnering with the n-Lorem Foundation provides us with the unique opportunity to apply our leading aseptic drug product manufacturing technology in support of nano-rare patients,” said Wayne Woodard, Founder and CEO of Argonaut. “I have been impressed with Stan’s vision and leadership with n-Lorem's charitable approach, and the overall progress of the foundation in such a short time. We are committed strategic partners as we understand that there are > 7,000 known rare to nano-rare diseases. Stan and I share a vision that these patient groups will have access to the life improving or lifesaving drugs that need to be developed. As such, we are honored to work with n-Lorem.” “For decades, patient care for rare disease and now nano-rare patients has improved with technological advancement. n-lorem has established the best partners in rare disease research, and we at Argonaut will be the final step in the sterile fill finish of these life-saving therapies. Our world class platform and expertise in drug product manufacturing were designed specifically for small batch drug product manufacturing that is specifically valuable for rare and orphan disease. This expertise and leadership is what we bring together with n-Lorem,” said Eric Blair, Chief Commercial Officer at Argonaut. About Argonaut Manufacturing Services, Inc. Argonaut Manufacturing Services is an FDA registered, FDB approved, ISO 13485:2016 cGMP contract manufacturing organization dedicated to providing custom manufacturing and supply chain solutions for life science, molecular diagnostics, and biopharmaceutical companies. Life sciences and molecular diagnostics services include formulation, filling, lyophilization, and kitting, while biopharmaceutical services feature state-of-the-art automated aseptic fill-finish equipment for sterile injectable drugs. All projects are supported by a senior project management group, full analytical quality control service offering and global shipping logistics. From procurement through distribution, Argonaut provides a wide range of flexible solutions for diverse outsourcing needs. About n-Lorem n-Lorem Foundation is a non-profit organization established to apply the efficiency, versatility, and specificity of antisense technology to charitably provide experimental antisense oligonucleotide (ASO) medicines to treat nano-rare patients diagnosed with diseases that are the result of a single genetic defect unique to only one or very few individuals. Nano-rare patients describe a very small group of patients who, because of their small numbers, have few if any treatment options. n-Lorem Foundation was created to provide hope to these nano-rare patients by developing individualized ASO medicines, which are short strands of modified DNA that can specifically target the transcripts of a defective gene to correct the abnormality. The advantage of experimental ASO medicines is that they can be developed rapidly, inexpensively and are highly specific. To date, n-Lorem has assisted in the development and treatment of 14 nano-rare patients and received over 100 applications for treatment with more than 50 nano-rare patients approved. n-Lorem was founded by Stanley T. Crooke, M.D., Ph.D., former chairman and CEO of Ionis Pharmaceuticals, who founded Ionis Pharmaceuticals in 1989 and, through his vision and leadership, established the company as the leader in RNA-targeted therapeutics.

Read More

MEDICAL

Bio-techne and Cygnus Technologies Present Plex Hek 293 Hcp 3G Immunoassay

Bio-Techne Corporation | April 13, 2022

Bio-Techne Corporation launched 3G assay for automated process impurity assessment on the EllaTM immunoassay platform ( NASDAQ: TECH ) and Cygnus Technologies, a division of Maravai LifeSciences ( NASDAQ: MRVI ). In cell and gene therapy applications, the purification of viral particles to reduce host cell protein (HCP) contamination is an important part of the viral production workflow. To guarantee HCP impurity clearance is performed in compliance with regulatory criteria, accurate quantification throughout process phases is required. The novel Simple Plex HEK 293 HCP 3G test uses a cartridge-based microfluidic design to deliver uniform and controlled assay conditions for HCP detection that is extremely accurate and reproducible. The test has a hands-free procedure and provides data in 90 minutes, providing pharmaceutical developers with a reliable and convenient tool for HCP impurity quantification. Simple Plex assays on the Ella platform, classic immunoassay methods, provide built-in calibration to reduce set-up time and user-dependent variability. The gold standard in HEK 293 HCP impurity quantification is Cygnus Technologies' HEK 293 HCP ELISA Kit, 3G. With high-tech antibody affinity extraction and heavy spectrometry procedures, the kit's antibody was tested for reactivity to almost 3,000 distinct HCPs present in HEK 293 strains. The kit has been tested with various viral vector-based medicinal compounds and in-process samples, demonstrating that it possesses the specificity and sensitivity to detect HEK 293 HCP contaminants with the reproducibility needed to meet regulatory requirements. The Simple Plex HEK 293 HCP 3G assay uses the same HEK 293 HCP antibodies from market leader Cygnus Technologies, ensuring the Cygnus ELISA's extensive HCP detection coverage and industry-recognized specificity, as well as the automated Ella platform's workflow advantages. We continue to enjoy the fruits of the Bio-Techne-Cygnus Technologies partnership as it provides the therapeutic development and manufacturing community an automated platform-based approach for HEK 293 host cell impurity testing, Fast and efficient process development and monitoring is crucial for biopharmaceutical companies providing a safe and efficacious product in a cost-effective manner." Will Geist, President of Bio-Techne's Protein Sciences Segment.

Read More

MEDTECH

IBM Research and Arctoris accelerate closed loop drug discovery with AI and Cloud

Arctoris | September 14, 2021

IBM Research and Arctoris announced they are investigating the application of AI and automation to accelerate closed loop molecule discovery. IBM Research has developed RXN for Chemistry, an online platform leveraging state-of-the-art Natural Language Processing (NLP) architectures to automate synthetic chemistry. Representing chemical reactions via SMILES (Simplified Molecular Input Line Entry System), the system is able to perform highly accurate reaction predictions using its powerful AI. Optimised synthetic routes are then used as input for RoboRXN, an automated platform for molecule synthesis. Arctoris has developed Ulysses, an end-to-end automated platform for drug discovery research. The platform ensures accuracy, precision, and reproducibility by leveraging robotic experiment execution and digital data capture technologies across cell and molecular biology and biochemistry/biophysics. Experiments conducted with Ulysses generate more than 100 times more datapoints per assay compared to industry standard, leading to deeper insights and accelerated progress compared to manual methods. The two platforms are now being combined for the first time in a research collaboration that will see new small molecule inhibitors for undisclosed targets being designed, made, tested, and analysed (DMTA) in an autonomous, closed loop approach. Concretely, IBM Research will design and synthesize novel chemical matter (Design, Make), to be profiled and evaluated by Arctoris (Test, Analyze), with the resulting data informing the subsequent iteration of the DMTA cycle. The collaboration is currently on-going; financial terms were not disclosed. About IBM Research For more than seven decades, IBM Research has defined the future of information technology with more than 3,000 researchers in 16 locations across five continents. Scientists from IBM Research have produced six Nobel Laureates, 10 U.S. National Medals of Technology, five U.S. National Medals of Science, six Turing Awards, 19 inductees in the National Academy of Sciences and 20 inductees into the U.S. National Inventors Hall of Fame. About Arctoris Arctoris is a biotechnology company founded and headquartered in Oxford with additional operations in Boston and Singapore. Ulysses, the unique technology platform developed by Arctoris, enables the company to conduct its R&D – from target via hit and lead to candidate – significantly faster, and with considerably improved data quality and depth. With its robotics, Arctoris generates richer, more reliable data, enabling better decisions both in human-driven and computational drug discovery, leading to higher success rates and an accelerated progression of programs towards the clinic. Led by an experienced team, Arctoris pursues its internal pipeline of small molecule inhibitors in different indications, and also partners with other biotech and pharma companies for small molecule and biologics discovery, with partners in the US, UK, Germany, Australia, Korea, China, and several other countries.

Read More